Merck's raltegravir combination beats efavirenz combo in treatment-naive HIV

Merck has presented previously unreported data showing that combination HIV therapy containing its integrase inhibitor, Isentress (raltegravir), confers better efficacy than that containing efavirenz (Bristol-Myers Squibb's Sustiva) in treatment-naïve adult patients.